Send to printer »

GEN News Highlights : Feb 5, 2007

Stratagene Gains Rights to over 150 microRNA Sequences

Licenses from Max Plank Innovation provides access to sequences for the development, manufacture, and sale of diagnostic kits.

Stratagene obtained the last of the four co-exclusive licenses to more than 150 microRNA sequences available from Max Planck Innovation, the technology transfer agency of the Max Planck Society.

"The potential of these sequences, when paired with our proprietary FullVelocity technology, should allow us to develop important detection tests for the molecular diagnostics marketplace," says Joseph A. Sorge, M.D., chairman and CEO.

Under the terms of the agreement, Stratagene will have the right to use the microRNA sequences for the development, manufacture, and sale of molecular diagnostic kits. Stratagene reports that it is particularly interested in the association of microRNAs with cancer.